Lifeboat Foundation

Researchers headed by a team at Mass Eye and Ear, Harvard Medical School, reported positive data from a Phase I clinical study evaluating a stem cell treatment known as cultivated autologous limbal epithelial cell transplantation (CALEC), in patients with significant chemical burns in one eye. Results from the study, reported in Science Advances, showed treatment to be safe and well tolerated in four patients who were followed for 12 months. The CALEC recipients experienced restored cornea surfaces, with two trial participants able to undergo subsequent corneal transplant, and two reporting significant improvements in vision without additional treatment.

The Phase I study was designed to determine preliminary safety and feasibility before advancing to a second phase of the trial, and the researchers consider the newly reported early findings to be promising. On the basis of these initial results the team started recruiting for a second phase of the trial that will investigate longer-term safety and efficacy in greater numbers of patients.

“Our early results suggest that CALEC might offer hope to patients who had been left with untreatable vision loss and pain associated with major cornea injuries,” said principal investigator Ula Jurkunas, MD, associate director of the Cornea Service at Mass Eye and Ear and an associate professor of ophthalmology at Harvard Medical School. “Cornea specialists have been hindered by a lack of treatment options with a high safety profile to help our patients with chemical burns and injuries that render them unable to get an artificial cornea transplant. We are hopeful with further study, CALEC can one day fill this crucially needed treatment gap.”

Talk with Your Allergy Care Team About Your Concerns.

If managing the social and emotional impacts of your atopic condition feels stressful and overwhelming, know that you’re not alone. More importantly, know that you don’t have to navigate those feelings alone either!

Your allergy healthcare team is a great place to start if you feel like you need additional support in managing your allergic condition. By discussing your concerns or struggles with them, they can offer useful evidence-based information, skills, and resources, as well as allied health care referrals.

Materials scientists aim to develop autonomous materials that function beyond stimulus responsive actuation. In a new report in Science Advances, Yang Yang and a research team in the Center for Bioinspired Energy Science at the Northwestern University, U.S., developed photo-and electro-activated hydrogels to capture and deliver cargo and avoid obstacles on return.

To accomplish this, they used two spiropyran monomers (photoswitchable materials) in the hydrogel for photoregulated charge reversal and autonomous behaviors under a constant electric field. The photo/electro-active materials could autonomously perform tasks based on constant external stimuli to develop intelligent materials at the molecular scale.

Continue reading “Hydrogel locomotion regulated by light and electric fields” »

Professor Ori Bar-Nur and his colleagues at ETH Zurich are pioneering the cultivation of muscle cells in the lab, currently using mouse cells as their primary model. While their current studies are centered on mouse cells, the team is also keen on exploring the potential of human and cow cells. The implications of their research are manifold: lab-cultured human muscle tissue could serve surgical needs, while human muscle stem cells might offer therapeutic solutions for those with muscle diseases. On the other hand, cultivating cow muscle tissue in labs could transform the meat industry by eliminating the necessity of animal slaughter.

For now, however, the ETH team’s research is focused on optimizing the generation of muscle stem cells and making it safer. They have now succeeded in doing so via a new approach.

The strange science experiment that blew a worm’s head off… and blew our minds.

This interview is an episode from @The-Well, our publication about ideas that inspire a life well-lived, created with the @JohnTempletonFoundation.

Continue reading “The beauty of collective intelligence, explained by a developmental biologist | Michael Levin” »

“Because of the heterogeneity of this disease, scientists haven’t found good ways of tackling it,” said Olivier Gevaert, PhD, associate professor of biomedical informatics and of data science.

Doctors and scientists also struggle with prognosis, as it can be difficult to parse which cancerous cells are driving each patient’s glioblastoma.

Continue reading “Scientists employ AI to predict brain cancer outcomes” »

The current influenza A vaccines utilize surface proteins as antigens, predominantly hemagglutinin. These antigens change each season, requiring new vaccine formulations and annual administration; thus, development of a universal influenza vaccine is a high priority. In an industry-sponsored phase 2a trial, investigators evaluated a recombinant, nanoparticle-based influenza A vaccine candidate containing influenza nucleoprotein (an invariant protein) and designed to elicit cell-mediated immunity. In all, 137 healthy adults (age range, 18–55) were randomized to receive vaccine (180 µg, 300 µg, or 480 µg) or placebo as a single intramuscular injection.

The vaccine elicited mild-to-moderate local and systemic reactogenicity at all active doses. Cell-mediated responses, as measured by nucleoprotein-specific interferon-gamma ELISpot, showed statistically significant increases compared with baseline in all vaccine groups. In addition to polyfunctional CD4 T-cells and increased antibody levels, the higher doses elicited CD8 T-cell responses. Preliminary evaluation of RT-PCR–positive influenza illness among participants was consistent with vaccine efficacy.

This candidate for a universal influenza A vaccine was safe and showed promise to elicit a strong immune-mediated response. Further studies are needed to evaluate protection against infection and disease compared with the currently available products. However, durability of protection will be the key requirement if a single administration of vaccine is to have a long-lasting effect.

Now maybe we can snack happily! I think this applies to regular food too? I can eat all the Chinese and Mexican and Italian food I want? Plus for people with genetic risks can’t this not help? I hope so.

Mice fed a high-sugar, high-fat diet for most of their lives managed to escape weight gain and protect their livers when they were treated with an experimental new drug.

The small-molecule drug was developed by a team led by The University of Texas Health Science Center at San Antonio (UT Health San Antonio). K nown by its chemical acronym CPACC, it works by limiting the entry of magnesium into the mitochondria, the parts of the cell in charge of generating energy and burning calories.

Continue reading “Scientists Develop Drug That Prevents Weight Gain in Junk-Food-Eating Mice” »

Welcome to this special issue, focusing on the potential of pluripotent stem cell (PSC)-based therapies and their paths toward clinical application. Since the establishment of human embryonic stem (ES) and induced pluripotent stem (iPS) cells in 1998 and 2007, respectively, significant progress has been made in differentiating PSCs into a broad range of somatic cells. We are now closer than ever before to having highly functional PSC-derived somatic cells at purity for transplantation therapies to complement damaged or diseased organs and restore their physiologic functions. Like organ transplantation, PSC-based therapies have the potential to regenerate damaged organs that cannot otherwise be healed by using small-molecule or antibody-based drugs.

In this issue, Kobold et al. present an overview of the history and current status of clinical studies utilizing human PSCs. Since the early 2010s, many clinical studies employing human ES cells have been initiated. By 2018, the number of such studies using human iPS cells had skyrocketed. Many PSC-based therapies are currently being tested to treat various pathologic conditions, including different neoplasms and diseases of the eye, adnexa, and circulatory system. However, there are still many diseases that require further efforts to interrogate the true potential of PSC-based therapies. To advance the use of PSC-based therapy to treat a wider range of pathologic conditions in the future, we must continue with extensive basic and clinical research to establish both efficacy and safety for such new therapies.

Although clinical research on PSC-based therapy for liver diseases has not received as much attention, there is much hope for it to become a real alternative to living-donor liver transplantation. Cardinale et al. provided a comprehensive summary of the recent studies on cell-based therapy for liver diseases. In addition, artificial livers generated through bioengineering efforts are now considered to be a viable option. Aside from traditional cell or organ transplantation to restore impaired liver function, transplantation aimed at treating the microenvironment, such as inflammation, in the liver is also an effective therapeutic strategy. Concurrent research efforts in both basic and clinical studies will be crucial in making PSC-based therapy for liver diseases a reality.